AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
5.20
+0.06 (1.17%)
At close: Jun 26, 2026, 4:00 PM EDT
5.20
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,645,381
Market Cap
187.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% |
| Dec 31, 2024 | 22 | -19 | -46.34% |
| Dec 31, 2023 | 41 | 5 | 13.89% |
| Dec 31, 2022 | 36 | 14 | 63.64% |
| Dec 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Tonix Pharmaceuticals Holding | 142 |
| MediWound | 121 |
| Arcturus Therapeutics Holdings | 111 |
| Compugen | 75 |
| Korro Bio | 49 |
| NovaBridge Biosciences | 30 |
| Outlook Therapeutics | 17 |
ANTX News
- 9 days ago - The Healthcare M&A Wave - Forbes
- 22 days ago - AN2 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 22 days ago - AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease - TheFly
- 22 days ago - AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire
- 5 weeks ago - AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - AN2 Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 6 weeks ago - AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink - TheFly
- 6 weeks ago - AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c) - TheFly